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MicroRNAs (miRNAs) have emerged as important regulators in human physiological and
pathological processes. Recent investigations implicated the involvement of miRNAs in the
immune system development and function and demonstrated an unexpected new regula-
tory level.We summarize the current knowledge about miRNA control in the development
of the immune system and discuss their role in the immune and inﬂammatory responses
with a special focus on eicosanoid signaling.
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INTRODUCTION
MiRNAs are small non-coding RNAs that control gene expression
in many cellular processes (He and Hannon, 2004; Grosshans and
Filipowicz, 2008). In 1993, lin-4 was the ﬁrst miRNA that was dis-
covered in the nematode Caenorhabditis elegans and was found to
regulate the gene lin-14 on posttranscriptional level during C. ele-
gans development (Wightman et al., 1993). Shortly after, a second
small miRNA involved in worm development, let-7, was identi-
ﬁed. However, at this time it was assumed that these RNAs are rare
exceptions and only present in nematodes. In 2001, three inde-
pendent publications reported the existence of several hundreds
of these small non-coding RNAs not only in nematodes but also
in murine and human cells. In the meantime, more than 1000
miRNAs have been identiﬁed (http://www.mirbase.org) and have
emerged as important regulators of gene expression. They play a
key role inmanyphysiological processes such as hematopoiesis, cell
proliferation, tissue differentiation, cell typemaintenance, apopto-
sis, signal transduction, organ development (Carissimi et al., 2009)
but also in tumorigenesis (Farazi et al., 2010).
Recent reports showed that miRNAs are important control ele-
ments in the mammalian immune system. Distinct expression
patterns in various hematopoietic organs and cell types points
to an important role in immune system development, home-
ostasis and response, and dysregulation can result in pathological
inﬂammatory responses and cancer (Baltimore et al., 2008; Liang
and Qin, 2009; Sonkoly and Pivarcsi, 2009). Here, we will give
a short overview about miRNAs important in the development
of the immune system and immune and inﬂammatory responses
with a special focus on eicosanoids as important mediators of the
inﬂammatory reactions.
BIOGENESIS PATHWAY OF miRNAs
MiRNAs are transcribed as long primary transcripts by RNA poly-
merase II to produce pri-miRNAs (Figure 1). Canonical miRNAs
are subsequently cleaved by Drosha, a member of the RNase-III
enzyme family, together with DGCR8, a double-stranded RNA-
binding protein (dsRBP). It results in ∼70-nucleotide precursors
(pre-miRNAs) containing imperfect stem loop structures (Lee
et al., 2003; He and Hannon, 2004; Carissimi et al., 2009). About
40% of the currently known miRNAs are located within introns
(mirtrons) which are processed by the spliceosome. Pre-miRNAs
are exported from the nucleus to the cytosol by a RanGTP-
dependent export complex containing Exportin 5 (Lund et al.,
2004; Du and Zamore, 2005). In the cytosol, pre-miRNAs are
subsequently processed by Dicer, another member of the RNase-
III enzyme family, together with the dsRBP TRBP to short 21–
23 nucleotide miRNA duplexes (Hutvagner et al., 2001). Only
one strand of the miRNA duplex is being incorporated into
a ribonucleoprotein complex (miRNP), also known as RNA-
induced silencing complex (RISC) whose core components are the
Argonaute family proteins (Ago1–4). The other strand is rapidly
degraded (Khvorova et al., 2003; Schwarz et al., 2003). MiRNPs are
then directed to their binding sites in the 3′ untranslated region
(UTR)of the targetmRNAandmediate either translational repres-
sion by interaction with the translational machinery or mRNA
destabilization through interaction with CCR4. In contrast, miR-
NAs direct mRNA cleavage when their sequences perfectly match
the target mRNA (Lewis et al., 2005; Baek et al., 2008).
miRNAs INVOLVED IN IMMUNE SYSTEM DEVELOPMENT
Recently, various miRNAs involved in the regulation of the mam-
malian immune system have been identiﬁed. First evidence came
from the overexpression of miRNAs in hematopoietic stem cells
which strongly affected B cell development after transplantation
in mice (Chen et al., 2004). This observation was further sup-
ported by inactivation of components of the miRNA machinery
which severely compromises lymphocyte development (Xiao and
Rajewsky, 2009). Conditional inactivation of Dicer in T and B
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FIGURE 1 | MiRNAs pathway. MiRNAs are transcribed as precursors
(pri-miRNA) by RNA polymerase II. The pri-miRNA are cleavaged by Drosha
together with DGCR8 into 70-nucleotide stem loop known as pre-miRNA, in
contrast mirtrons are processed by the spliceosome. The pre-miRNAs are
transported to the cytosol by Exportin 5, where they are further processed by
Dicer together with TRBP to mature miRNA. The mature miRNA, indicated in
red, is incorporated into a ribonucleoprotein complex (miRNP), also known as
RNA-induced silencing complex (RISC) whose core components are the
Argonaute family proteins (Ago1–4). miRNPs either mediate mRNA
destabilization, translational repression, or mRNA cleavage.
lymphocytes resulted in an up to 10-fold reduction in total lym-
phocyte amount where regulatory T cells were mostly affected
(Cobb et al., 2005). A conditional deletion of Ago2 compromises
the development of B and erythroid cells (O’Carroll et al., 2007)
whereas Dicer knockout seems to completely block the pro- to
pre-B cell transition (Koralov et al., 2008). Subsequently, expres-
sion proﬁling combined with bioinformatic analyses attempted to
identify individual miRNAs responsible for these phenotypes to
explain the effect of miRNAs on B and T cell homeostasis and
response.
One prominent example is miR-150. The miRNA shows sig-
niﬁcant changes in the expression levels during lymphoid devel-
opment. It is highly expressed in mature B and T cells, but not in
their progenitors (Monticelli et al., 2005; Zhou et al., 2007). One of
the predicted targets of miR-150 was c-Myb, which is a transcrip-
tion factor controlling multiple steps of lymphocyte development.
Rajewsky and coworkers have demonstrated that miR-150 con-
trols c-Myb expression in vivo. They further showed that the
partial block of B cell development through miR-150 expression
was indeed due to downregulation of c-Myb (Xiao et al., 2007).
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These ﬁndings highlight thatmiR-150 is responsible for the transi-
tion to the pro-B to the pre-B cell stage during B cell differentiation
(Xiao et al., 2007). In addition,miR-150 overexpression can restore
correct T cell differentiation in Dicer deﬁcient T cells.
MiR-155 is a further example of a miRNA with a speciﬁc func-
tion in lymphoid differentiation. Its expression is increased during
activation of B and T cells as well as in activated monocytes (Vasi-
latou et al., 2010). Rajewsky and coworkers analyzed the role of
miR-155 in regulating T helper cell differentiation into T helper
cell 1 (TH1) and TH2. Furthermore,miR-155 knockout mice indi-
cated that miR-155 is required for an optimal T cell-dependent
antibody response. MiR-155 exerts this control by regulation of
cytokine production, e.g., interleukin-4 (IL-4) and interferon-γ
(IFN-γ; Thai et al., 2007). Bradley and coworkers performed a
transcriptome analysis of mice deﬁcient for B cell integration
cluster/miR-155 (bic/miR-155) and identiﬁed miR-155 regulated
genes, including various cytokines, chemokines, and transcription
factors (Rodriguez et al., 2007).
MiR-181a has also been identiﬁed as a positive regulator of B
lymphocyte differentiation. Furthermore, it is involved in thymic
T cell differentiation by activation of the T cell receptors (Chen
et al., 2004; Li et al., 2007).
A regulatory circuit involving miR-17-5p, miR-20a, miR-106a,
and the transcription factors AML1 and M-CSF have been shown
to control monocytopoiesis. The miRNAs are downregulated in
unilineage monocytic cultured cells, whereas AML1 is upregu-
lated at protein level but not on mRNA level. Overexpression of
miR-17-5p, miR-20a, and miR-106a downregulates AML1 pro-
tein expression, leading to downregulation of the M-CSF receptor,
enhanced blast proliferation, inhibition of monocytic differenti-
ation, and maturation. Additionally, AML1 inhibits transcription
of the miR-17-5p-92 and the miR-106a-92 cluster as a negative
feedback (Fontana et al., 2007).
The number of miRNAs with speciﬁc function in immune
system constantly increases and is comprehensively reviewed else-
where (Baltimore et al., 2008; Sonkoly and Pivarcsi, 2009). It
demonstrates impressively that miRNAs display a highly impor-
tant, but previously unrecognized level of control of gene expres-
sion in the immune system.
miRNAs AND EICOSANOIDS
Beyond their crucial role in immune systemdevelopment,miRNAs
are also involved in immune and inﬂammatory responses. It
became apparent that several miRNAs are induced by inﬂam-
matory stimuli (reviewed in Sheedy and O’Neill, 2008). Of note,
miR-146 and miR-155 induce pro-inﬂammatory stimuli like
interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-α), and
toll like receptor (TLR) and have been involved in the onset of
several inﬂammatory diseases like psoriasis or rheumatic arthritis
(Sheedy and O’Neill, 2008).
Eicosanoids like leukotrienes and prostaglandins are biolog-
ically active lipids and important pro-inﬂammatory mediators
involved in pathological processes such as chronic inﬂammation
and carcinogenesis. Biosynthesis of eicosanoids starts with the
release of arachidonic acid from membranes by phospholipases
followed by the metabolism of the released arachidonic acid by
cyclooxygenases, lipoxygenases, and P450 epoxygenase pathways
(Figure 2; Wang and Dubois, 2010). Recent ﬁndings indicate that
several miRNAs are also involved in the control of key enzymes of
the eicosanoid production.
miRNAs REGULATION IN PROSTANOID BIOSYNTHESIS
Cyclooxygenases (COX) exist in two isoforms, COX-1 and COX-
2, both of which catalyze the conversion of arachidonic acid
to prostaglandin H2 which is further metabolized to the var-
ious prostaglandins and thromboxane A2. Prostaglandins and
leukotrienes exert their biological effects in an autocrine or
paracrinemanner by binding to their cognate cell surface receptors
(Wang and Dubois, 2010). COX-1 was thought to be a housekeep-
ing enzyme responsible for maintaining basal prostanoid levels
that are important for tissue homeostasis. By contrast, COX-2 is
undetectable in most tissues, but is strongly induced in response
to hypoxia, inﬂammatory cytokines, and other stressors.
COX-2 expression is regulated at various levels (Harper and
Tyson-Capper, 2008; Mbonye and Song, 2009). Numerous tran-
scription factors such as nuclear factor-κB (NF-κB), activator
protein-1 (AP-1), or cAMP-responsive element binding protein
(CREP) are involved in the transcriptional regulation (Yamamoto
et al., 1995;Kang et al., 2007).Moreover,COX-2 expression is inﬂu-
enced by chromatin remodeling (Deng et al., 2003). An additional
level of regulation is the COX-2 mRNA stability and transla-
tion efﬁciency. Several cis-acting sequences, like AU-rich elements
(ARE), have been identiﬁed within the ∼2000 nt long 3′ UTR.
Trans-acting proteins, like HuR or the CUG triplet repeat-RNA-
binding protein 2 (CUGBP2), recognize these cis-acting sequences
and inﬂuence the stability of the COX-2 mRNA (Mukhopadhyay
et al., 2003; Subbaramaiah et al., 2003). The use of an alternative
polyadenylation signal has also be shown to affect mRNA stability
and translation (Hall-Pogar et al., 2005).
Recent studies identiﬁed miRNAs as additional players in the
posttranscriptional control of COX-2 expression. Chakrabarty
et al. (2007) observed that miR-199a* and miR-101a share sim-
ilar temporal and spatial expression proﬁles like COX-2 in the
mouse uterus during implantation. Further studies revealed that
COX-2 expression is post-transcriptionally regulated by a direct
interaction of miR-101a and miR-199a* with COX-2 3′ UTR in
mice (Chakrabarty et al., 2007). The authors showed a simi-
lar dependency during endometrial carcinogenesis. An elevated
COX-2 level correlated with a decreased expression of miR-101a
and miR-199a* suggesting that these two miRNAs are involved in
the regulation COX-2 expression in endometrial cancer in mice
(Daikoku et al., 2008).
An inverse correlation between COX-2 and miR-101a expres-
sion has also been observed in human colon cancer cells. Strillacci
et al. (2009) showed that miR-101 decreases COX-2 protein levels
in HT-29 cells by translational repression. This coincides with the
observation that reduced miR-101 expression correlates with high
levels of COX-2 protein expression in colon cancer tissues and liver
metastases derived from colorectal cancer patients (Strillacci et al.,
2009). Hiroki et al. (2010) found a similar relationship between
COX-2 expression and miR-101. They identiﬁed a strong pos-
itive immunoreactivity of COX-2 which signiﬁcantly correlated
with the downregulation of miR-101 in patients with endome-
trial serous carcinoma (Hiroki et al., 2010). A similar inverse
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FIGURE 2 | Overview of arachidonic acid cascade and miRNAs involved
in regulation. Arachidonic acid is released from cellular membranes by
cytosolic phospholipase A2 (PLA2). The free arachidonic acid can further be
converted to eicosanoids by three different pathways involving lipoxygenases
(LO), cyclooxygenases (COX), and the cytochrome P450 monooxygenase
pathway (not shown), respectively. COX enzymes catalyze the conversion of
arachidonic acid to prostaglandin G2, which is reduced to prostaglandin H2
(PGH2). By speciﬁc prostaglandin (PG) and thromboxane (TXA2) synthases,
PGH2 is subsequently converted to different prostaglandins and thromboxane
A2. Different LO enzymes convert the arachidonic acid to biologically active
metabolites such as leukotrienes and hydroperoxyeicosatetraenoic acids
(HPETEs). In the leukotriene pathway, arachidonic acid is converted to
5-HPETE, which is further metabolized to the unstable leukotriene A4 (LTA4).
LTA4 is converted to LTB4 or the cysteinyl-containing LTC4, LTD4, and LTE4.
The red boxes highlight which miRNAs are involved in the regulation of key
enzymes of the arachidonic acid cascade.
relationship between COX-2 and miR-101a expression have been
observed in mammary gland indicating that miR-101 regulates
cell proliferation via COX-2 expression (Tanaka et al., 2009).
The expression pattern of the miR-26b is also inversely cor-
related with COX-2 expression in desferrioxamine (DFOM)-
treated carcinoma cells of the nasopharyngeal epithelium. Here,
a feedback of COX-2 expression on the miRNA level has been
demonstrated (Ji et al., 2010).
Lukiw and coworkers reported that herpes simplex virus-1
(HSV-1) infection of human brain cells induces miR-146a that
is associated with pro-inﬂammatory signaling in stressed brain
cells and Alzheimer’s disease. It has been shown that HSV-1
infection leads to the upregulation of pro-inﬂammatory mark-
ers such as cytosolic phospholipase A2, COX-2, and IL-1β, but also
of miR-146a, coupled to a decreased expression of the immune
system repressor complement factor H (CFH). The authors sug-
gest that the miR-146a mediated downregulation of CFH and
the subsequent upregulation of key members of the arachidonic
acid cascade contribute to Alzheimer-type neuropathological
changes (Hill et al., 2009). Recent studies demonstrate that ﬁbro-
blasts from patients with chronic obstructive pulmonary disease
(COPD) produce increased amounts of prostaglandin E2 (PGE2)
in response to the inﬂammatory cytokines IL-1β and TNF-α. The
decreased expression level of miR-146a leads to reduced degrada-
tion of COX-2 mRNA and overproduction of PGE2. This speciﬁc
miR-146a overexpression in COPD ﬁbroblast is a new pathophys-
iologic mechanism contributing to the abnormal inﬂammatory
response in COPD patients (Sato et al., 2010).
Jing et al. (2005) have shown that miR-16 induces TNF-α and
COX-2 mRNA degradation. Interestingly, this regulation is not
only dependent on the enzymes of miRNA dependent decay but
also on tristetraproline (TPP) which binds ARE and directs rapid
mRNA decay (Jing et al., 2005). A direct interaction for miR-16-1
with its binding site on the target mRNA as well as an inﬂu-
ence on ARE-mediated mRNA stability has been demonstrated.
MiR-16 contains an 8-nt-sequence (UAAAUAUU) that is comple-
mentary to the ARE. MiR-16 is required for ARE-mediated decay
in a sequence speciﬁc manner and requires the ARE-binding pro-
tein TTP which is involved in the formation of the decay complex.
This shows that miRNAs which target ARE appear to be an essen-
tial step in ARE-mediated regulation (Jing et al., 2005; Calin et al.,
2008; von Roretz and Gallouzi, 2008).
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Another miRNA involved in ARE-mediated decay was recently
identiﬁed by Filipowicz and coworkers. They showed that HuR
was able to rescue translation of repressed cationic amino acid
transporter-1 (CAT-1) mRNA, probably by interfering with the
association of miR-122 with AREs within the 3′ UTR of CAT-1
mRNA (Bhattacharyya et al., 2006). Since the stability of COX-2
mRNA is also dependent on HuR (Subbaramaiah et al., 2003) it
can be speculated that miR-122 can also be involved in COX-2
regulation.
A further interesting aspect is if and how miRNAs itself are
controlled by prostanoids. In a recent report, Ruan and cowork-
ers found that prostacyclin (PGIe) inﬂuence expression of several
miRNAs (upregulation of miRNA-711, miRNA-744, and miRNA-
148b, downregulation of miR-466f-3p, miR-148a, miR-7a, miR-
374). The regulation was mediated via the PGI2 receptor and was
found to inhibit insulin-mediated lipid deposition in a mouse adi-
pose tissue derived primary culture cell line (Mohite et al., 2011).
This study indicates that miRNA regulation may be involved in a
wide range of pathophysiological processes.
miRNA REGULATION IN LEUKOTRIENE BIOSYNTHESIS
The 5-lipoxygenase (5-LO) enzyme interacts with a 5-LO activat-
ing protein (FLAP) to convert arachidonic acid to the unstable
leukotriene A4 (LTA4). FLAP is essential for cellular leukotriene
biosynthesis since it binds arachidonic acid andpresents it to 5-LO.
LTA4 is subsequently converted into biologically active leukotriene
B4 (LTB4) by LTA4 hydrolase or to leukotriene C4 (LTC4) by
LTC4 synthase. LTC4 canbe enzymatically converted to leukotriene
D4 which is metabolized to leukotriene E4 (Figure 2; Wang and
Dubois, 2010).
Gonsalves and Kalra examined the effect of hypoxia on FLAP
expression in human pulmonary vascular endothelial cells and
in a transformed human brain endothelial cell line. They could
demonstrate that hypoxia-mediated FLAP expression is regulated
at the level of transcription. Furthermore, FLAP expression is neg-
atively regulated by miR-135a and miR-199a-5p which provides a
novel mechanism for the ﬁne tuning of leukotriene production
(Gonsalves and Kalra, 2010).
Recchiuti et al. (2011) identiﬁed a set of miRNAs that were tem-
porally regulated in a self-limited acute inﬂammatory response
and inﬂuenced by the lipid mediator resolving D1 (RvD1) which
is involved in the resolution of inﬂammation. MiR-21, miR-146b,
and miR-219 were upregulated by RvD1. They analyzed the effect
of miRNA overexpression on genes involved in inﬂammatory and
immune response and identiﬁed a plethora of candidates includ-
ing cytokines and proteins involved in immune reactions like
NF-κB. Based on these data the authors create networks of target
genes of RvD1-regulated miRNAs (Recchiuti et al., 2011). 5-LO
was among the identiﬁed targets of miR-219. Overexpression of
miR-219 gave a reduction of 5-LO protein by 20% and a reduced
leukotriene production. However, since no direct binding site for
miR-219 is predicted within the 5-LO 3′ UTR the effect may be
indirect (Recchiuti et al., 2011).
An interesting report by Dincbas-Renqvist et al. (2009) showed
that 5-LO can interact with the C-terminal domain of human
Dicer. The interaction between the 5-LO binding domain with
a dicer fragment was shown to enhance 5-LO enzymatic activity
in vitro, whereas 5-LO modiﬁed the processing activity of Dicer.
These results suggest that the processing of speciﬁc miRNAs by
Dicer might be regulated by 5-LO/Dicer interaction in inﬂamma-
tory and cancer cells (Dincbas-Renqvist et al., 2009).
CONCLUSION AND PERSPECTIVES
Eicosanoids including leukotrienes and prostaglandins are impor-
tant biologically active lipids regulating immune responses in
the body (Wang and Dubois, 2010). Recent evidence suggests
that miRNAs are indeed involved in inﬂammatory signaling, yet
research is clearly still at the beginning and the extent and impor-
tance of miRNA mediated regulation remains to be discovered.
The number of identiﬁed miRNAs involved in eicosanoid path-
way continues to grow and the examples reviewed here may just
be the tip of an iceberg with the complexity of their possible role in
the inﬂammatory processes not yet been clariﬁed. Many questions
are still open like how many miRNAs are involved in eicosanoid
signaling, how these RNAs are regulated, which steps in the signal-
ing cascade are targeted, are they associated with acute, chronic,
or resolving inﬂammation, are they key regulators or just involved
in ﬁne tuning? A better understanding of the regulation of lipid
mediator formation by miRNAs will be of interest not only for the
further elucidation of lipid signaling but may open a new avenue
in the development of new therapeutic concepts for treatment of
inﬂammation and cancer.
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